C

California Allergy and Asthma Medical Group | Los Angeles, CA

Research site
(Unclaimed)
Location
1950 Sawtelle Boulevard Suite 138, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib
Ciclesonide Hydrofluoroalkane
HFA
Symbicort®
Cetirizine
PF-07275315
etrasimod
GB001
Formoterol
Rezpeg

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 15 total trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07264660

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Trial sponsors

AbbVie logo
C
Pfizer logo
Sumitomo Pharma logo
A
A
G
K
Nektar Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems